eMedicine Specialties > Dermatology > Metabolic Diseases

Calcinosis Cutis

Julia R Nunley, MD, Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center
Lydia M E Jones, MD, Staff Physician, Department of Dermatology, Virginia Commonwealth University

Updated: Jan 27, 2009

Introduction

Background

Calcinosis cutis is a term used to describe a group of disorders in which calcium deposits form in the skin. Virchow initially described calcinosis cutis in 1855. Calcinosis cutis is classified into 4 major types according to etiology: dystrophic, metastatic, iatrogenic, and idiopathic. A few rare types have been variably classified as dystrophic or idiopathic. These include calcinosis cutis circumscripta, calcinosis cutis universalis, tumoral calcinosis, and transplant-associated calcinosis cutis.

Pathophysiology

In all cases of calcinosis cutis, insoluble compounds of calcium are deposited within the skin due to local and/or systemic factors. These calcium salts consist primarily of hydroxyapatite crystals or amorphous calcium phosphate. The pathogenesis of calcinosis cutis is not completely understood and a variety of factors allow for different clinical scenarios to occur.

Metabolic and physical factors are pivotal in the development of most cases of calcinosis. Ectopic calcification can occur in the setting of hypercalcemia and/or hyperphosphatemia when the calcium-phosphate product exceeds 70 mg²/dL², without preceding tissue damage. These elevated extracellular levels may result in increased intracellular levels, calcium-phosphate nucleation, and crystalline precipitation. Alternatively, damaged tissue may allow an influx of calcium ions leading to an elevated intracellular calcium level and subsequent crystalline precipitation. Tissue damage also may result in denatured proteins that preferentially bind phosphate. Calcium then reacts with bound phosphate ions leading to precipitation of calcium phosphate.

Frequency

United States

Specific incidence and frequency data are unavailable.

International

Dystrophic calcinosis cutis is most common. Specific incidence and frequency data are unavailable.

Mortality/Morbidity

Calcinosis cutis generally is a benign process. When present, morbidity is related to the size and location of the calcification.

• Lesions may become painful, limit mobility of an adjacent joint, or compress adjacent neural structures.
• Ulceration and secondary infection may occur.
• Vascular calcification may result in ischemia and necrosis of the affected organ.

Race

Tumoral calcinosis is more common in blacks of South African heritage.

Sex

No sex predilection is documented.

Age

• Subepidermal calcified nodules are more common in children.
• Calcinosis cutis circumscripta tends to arise in the second half of life.
• Calcinosis cutis universalis occurs in the second decade of life.
• Tumoral calcinosis usually arises in the first or second decade of life.

Clinical

History

Most lesions of calcinosis cutis develop gradually and are asymptomatic. However, the history and evolution of the lesions depend on the etiology of the calcification. Patients with dystrophic calcification may provide a history of an underlying disease, a preexisting dermal nodule (which represents a tumor), or an inciting traumatic event. Patients with metastatic calcification most frequently have a history of chronic renal failure. Cases of idiopathic calcinosis cutis usually are not associated with previous trauma or disease. Those who develop iatrogenic calcinosis cutis generally have a history of recent hospitalization.

Physical

The clinical presentation of calcinosis cutis can vary according to the diagnosis and underlying process. In general, multiple, firm, whitish dermal papules, plaques, nodules, or subcutaneous nodules are found in a distribution characteristic for the specific disorder. At times, these lesions may be studded with a yellow-white, gritty substance. Not infrequently, the lesions spontaneously ulcerate, extruding a chalky, white material. Most lesions are asymptomatic, though some may be tender, and others may restrict joint mobility. When severe, vascular calcification can cause diminished pulses and cutaneous gangrene.

• Dystrophic calcinosis cutis: Calcification is usually localized to a specific area of tissue damage, though it may be generalized in some disorders.
• Metastatic calcinosis cutis: Calcium deposition frequently is widespread. Large deposits are frequently found around large joints, such as knees, elbows, and shoulders, in a symmetrical distribution. Visceral organ deposition of calcium in the lung, kidneys, blood vessels, and stomach actually occurs more frequently than deposition within the skin or muscle.
• Idiopathic calcinosis cutis: Calcification most commonly is localized to one general area.
• Iatrogenic calcinosis cutis: Calcification generally is located at the site of an invasive procedure, though diffuse deposition may occur.

Causes

Disorders of calcinosis cutis may be categorized according to the type of calcification process, ie, dystrophic, metastatic, idiopathic, and iatrogenic.

• Dystrophic calcification occurs in the setting of normal serum calcium and phosphate levels. The primary abnormality is damaged, inflamed, neoplastic, or necrotic skin. Tissue damage may be from mechanical, chemical, infectious, or other insults.
  • Localized tissue damage: Extraosseal calcification can occur in the setting of many local and destructive processes, including burns, arthropod bites, acne lesions, varicose veins, and rhabdomyolysis, among others.
    • Trauma
    • Inflammatory processes - Acne or insect bites
    • Varicose veins
    • Infections: Necrotic tissue produced by an infectious process may subsequently become calcified. Some infectious granulomas produce 1,25-vitamin D. Infections that may result in calcinosis cutis include onchocerciasis, cysticercosis, histoplasmosis, cryptococcosis, and intrauterine herpes simplex.
    • Tumors: Benign and malignant tumors may develop calcification. Pilomatrixoma, or calcifying epithelioma of Malherbe, is the most common tumor that becomes calcified. Epithelial cysts and syringomas also have a significant tendency to calcify. Foci of calcification commonly are seen in histologic sections of basal cell carcinomas. In rare cases, melanocytic nevi, malignant melanoma, atypical fibroxanthoma, hemangioma, pyogenic granuloma, seborrheic keratoses, neurilemomas, and trichoepitheliomas show foci of calcification.
  • Generalized tissue damage
    • Connective tissue diseases: Examples are dermatomyositis^1,2 ; lupus erythematosus^3,4,5,6 ; systemic sclerosis; and calcinosis cutis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, telangiectasias (CREST).
    • In dermatomyositis, calcification occurs 3 times more commonly in juvenile dermatomyositis than the adult-onset form and may be seen in 30-40% of patients. Calcification is accentuated over joints, sparing the digits. Aggressive corticosteroid therapy decreases the incidence of calcification. In lupus erythematosus, calcification is rare and usually an insignificant incidental radiologic finding. Calcification occurs most frequently with long-standing systemic disease, and though calcification may develop in lesions of lupus profundus, it usually is not associated with panniculitis. However, an associated myositis may be present. Lesions characteristically are on the extremities.Regarding scleroderma, systemic scleroderma and CREST syndrome are related diseases frequently associated with the late development of tissue calcification.
    • Panniculitis: Subcutaneous fat necrosis of the newborn typically affects full- or post-term newborns within the first few days to weeks of life. Necrosis of subcutaneous tissues, predominantly on the shoulders and buttocks, results in nodules and plaques that may become calcified. The cause is unknown. Possible inciting events are obstetric trauma, maternal pre-eclampsia or diabetes, or neonatal hypothermia or hypoxia. Pancreatitis or pancreatic malignancy may result in inflammation of the panniculus. The combination of fatty acids released by damaged fat cells and calcium may lead to calcium salt formation.
    • Inherited disorders: Examples are Ehlers-Danlos syndrome, Werner syndrome, pseudoxanthoma elasticum, and Rothmund-Thompson syndrome. Ehlers-Danlos syndrome is a group of inherited disorders of collagen metabolism. Individuals with Ehlers-Danlos type I may develop calcification in healing surgical scars and subcutaneous nodules.Werner syndrome is an inherited disorder of premature aging. Soft tissue calcification may involve the ligaments, tendons, synovia, vasculature, and/or subcutaneous tissue.Pseudoxanthoma elasticum is a disorder of abnormal elastic fibers. Calcification occurs in the elastic fibers causing rupture. Late in the disease, collagen fibers may become calcified.In Rothmund-Thomson syndrome, small, yellow papules of calcification may be numerous on the extremities.
• Metastatic calcification arises in the setting of abnormal calcium or phosphate metabolism and is generally associated with hypercalcemia and/or hyperphosphatemia.
  • Primary or secondary hyperparathyroidism: In primary hyperparathyroidism, the parathyroid glands become hyperplastic and autonomously overproduce parathyroid hormone. Secondary hyperparathyroidism is a functional response to hypocalcemia. The causes of hypocalcemia may be numerous, but the most common cause is chronic renal failure.
  • Paraneoplastic hypercalcemia: Hypercalcemia may occur as part of a malignancy syndrome due to bony metastases or the production of an abnormal hormone that directly affects calcium and bone metabolism.
  • Destructive bone disease: Malignancy and other conditions, such as Paget disease, may induce enough bone destruction to cause hypercalcemia.
  • Milk-alkali syndrome: Uncommon today, this syndrome is caused by excessive consumption of sodium bicarbonate and calcium-containing compounds. The result is a metabolic alkalosis with hypercalcemia, hyperphosphatemia, nephrocalcinosis, and renal failure.
  • Excessive vitamin D: Overconsumption of vitamin D may increase GI calcium absorption, as well as renal calcium reabsorption, giving rise to hypercalcemia. This mechanism is relatively uncommon.
  • Sarcoidosis: The sarcoidal granuloma may overproduce 1,25-vitamin D, with subsequent hypercalcemia and an elevated calcium-phosphate product.
  • Chronic renal failure: This is the most common setting in which metastatic calcification occurs. Chronic renal failure affects many factors in calcium metabolism. Hyperphosphatemia due to decreased renal clearance occurs relatively early. Hypocalcemia is the direct result of this hyperphosphatemia and worsened by vitamin D deficiency due to renal failure. As a compensatory measure, excessive parathyroid hormone is produced. This augmentation results in increased calcium and phosphate mobilization; an elevated solubility product; and, subsequently, the formation and precipitation of calcium salts.
  • Calciphylaxis: This is a poorly understood, highly morbid process that most commonly affects patients with end-stage renal disease. Calcification occurs in the intima of the blood vessels and subcutaneous tissue. Microthrombi formation is a frequent finding. The exact mechanism remains unknown, but the most common unifying disorders are renal failure, hypercalcemia, hyperphosphatemia, and hyperparathyroidism.
• Idiopathic calcinosis cutis occurs in the absence of known tissue injury or systemic metabolic defect.
  • Idiopathic calcinosis of scrotum, penis, or vulva: Calcification may occur after trauma, or it may occur in the absence of known tissue injury. Calcinosis cutis of the penis may also result from calcification of an epidermal cyst.
  • Milia-like idiopathic calcinosis cutis^7,8,9,10 : Many cases have been associated with Down syndrome and/or syringoma formation. Lesions are usually multiple and occur on the trunk, limbs, and face. The etiology remains controversial, but some evidence of calcium deposition in the sweat glands is present.
  • Subepidermal calcified nodule: These lesions usually develop in early childhood and are typically solitary, though multiple lesions can also be present. The nodules most commonly occur on the face, though they may occur anywhere. The pathogenesis is unknown, but the lesions may be due to calcification of components of adnexal structures.
  • Tumoral calcinosis: This may be caused by an error in renal phosphate metabolism resulting in hyperphosphatemia. General characteristics of the calcified nodules are a large size, a juxta-articular location, progressive enlargement, a tendency to recur after surgical removal, and the ability to encase the adjacent normal structures. The most common locations of calcification are the hip, elbow, scapula, foot, leg, knee, and hand. Tumoral calcinosis is often familial, and the hereditary pattern suggests that it is an autosomal recessive trait. Vitamin D deficiency may also be associated with hyperphosphatemia.
  • Calcinosis cutis circumscripta and calcinosis universalis: These forms are rare and may be due to altered ground substances. Calcinosis cutis circumscripta generally occurs earlier and tends to involve the extremities, whereas calcinosis universalis occurs later and is usually more widespread. Both have been associated with trauma, foreign body reaction, and (on occasion) scleroderma.
  • Transplant-associated calcinosis cutis^11,12,13 : In addition to calciphylaxis, numerous cases of calcinosis cutis have been described in transplant recipients. Although calcinosis cutis appears to be most common after renal transplantation, it is also described in liver, heart, and lung transplantation. The etiology of this calcification is unknown. Perhaps patients are infused with large numbers of blood products containing citrate and calcium that create an environment that favors calcification. The role of other factors remains to be elucidated.
• Iatrogenic calcinosis cutis arises secondary to a treatment or procedure.¹⁴
  • Parenteral administration of calcium or phosphate: The intravenous administration of solutions containing calcium or phosphate may cause the precipitation of calcium salts and lead to calcification.
  • Parental inorganic phosphate
  • Tumor lysis syndrome: Cutaneous calcification associated with tumor lysis syndrome is due to several factors, including chemotherapy-induced tissue damage with resultant hyperphosphatemia, hypocalcemia, hyperuricemia, and the potential for acute renal failure. Hypocalcemia frequently requires parenteral calcium use, increasing the possibility of tissue calcification.
  • Repeated heel sticks in the newborn: Calcium salt deposition may occur in newborns at sites of repeated heel sticks.
  • Prolonged use of calcium-containing electrode paste: Prolonged placement of electrode pastes containing calcium on abraded skin in diagnostic procedures such as electroencephalography, electromyography, or brainstem auditory evoked potential testing may result in calcium deposition at the placement site.

Differential Diagnoses

Milia
Molluscum Contagiosum
Mycetoma
Osteoma Cutis
Warts, Genital
Xanthomas

Other Problems to Be Considered

Gouty tophi
Progressive osseous hyperplasia
Subcutaneous cholesterol crystals

Workup

Laboratory Studies

• Tests of serum calcium, inorganic phosphate, alkaline phosphatase, and albumin levels may be helpful.
  • An elevation in serum calcium and alkaline phosphatase levels with a decrease in the inorganic phosphate level is suggestive of hyperparathyroidism.
  • One can further calculate the calcium-phosphate product to determine if the threshold of 70 mg²/dL² is exceeded.
  • An albumin value is needed to interpret the significance of hypocalcemia or hypercalcemia. Calcium is highly protein bound, and abnormalities in the albumin concentration may cause clinically insignificant abnormalities of calcium concentration.
• Serum blood urea nitrogen and creatinine concentrations can be obtained to measure renal function.
• On the complete blood cell count with differential, hematologic abnormalities may suggest an underlying malignancy or lupus erythematosus.
• If milk-alkali is suspected, the plasma bicarbonate or arterial pH value may indicate the presence of a metabolic alkalosis.
• The parathyroid hormone concentration is a direct measurement for hyperparathyroidism.
• Creatine kinase and aldolase value may be significantly abnormal in cases of dermatomyositis, myositis, or rhabdomyolysis.
• Serum amylase or lipase levels are markers of pancreatic disease.
• Antinuclear antibody testing is helpful in screening for lupus erythematosus.
• In patients with scleroderma, the presence of SCL-70 (topoisomerase) antibody portends a poor prognosis.
• Vitamin D levels should be determined to evaluate the possibility of vitamin D excess or deficiency.¹⁵
• A test of the 24–hour urinary excretion of calcium and/or inorganic phosphate may be useful.

Imaging Studies

• Radiographic examination may demonstrate the extent of tissue calcification.
• Bone scintigraphy with radiolabeled phosphate compounds (technetium Tc 99m methylene diphosphonate [MDP]) is useful in evaluating nonvisceral soft tissue calcification; this test is more sensitive than plain radiography.^16,17
• CT allows for the identification of visceral and nonvisceral calcification. CT is infrequently used in evaluating calcinosis cutis and primarily used in assessing tumoral calcinosis.
• MRI is of limited utility in evaluating calcified structures, but calcific deposits have characteristic patterns. The granulomatous foreign body reaction in tumoral calcinosis is evident.

Procedures

• Findings on biopsy and histopathologic examination of a cutaneous lesion are diagnostic.
• Results of fine-needle aspiration cytology of a skin nodule may also be diagnostic.

Histologic Findings

On biopsy, granules and deposits of calcium are seen in the dermis, with or without a surrounding foreign-body giant cell reaction. Alternatively, massive calcium deposits may be located in the subcutaneous tissue. In areas of necrosis, calcium deposition is frequently found within the walls of small and medium-sized blood vessels. Calcium deposition may be confirmed on Von Kossa and alizarin red stains.

Treatment

Medical Care

• Medical therapy of calcinosis cutis is limited and of variable benefit. When identified, the underlying problem should be corrected.
• Intralesional corticosteroids may be beneficial because of their anti-inflammatory and inhibitory effects on fibroblast activity.
• Probenecid and colchicine have been beneficial in some individuals.
• Magnesium or aluminum antacids may be effective phosphate binders in patients with hyperphosphatemia. However, the use of these agents in patients with renal insufficiency may result in magnesium or aluminum toxicity.
• Sodium etidronate and diphosphonates may reduce bone turnover and inhibit the growth of ectopic hydroxyapatite crystals. However, prolonged treatment is necessary, and paradoxical hyperphosphatemia may result.
• Myo-inositol hexaphosphonate is a dietary substance shown to inhibit the crystallization of calcium salts. Recent animal studies have demonstrated a reduction in calcinosis cutis lesions with topical myo-inositol hexaphosphate. This potentially could be of benefit in humans.^18,19
• Warfarin has shown benefit in some.
• The use of the calcium-channel blocker diltiazem over at least 5 years has variable benefits. The therapeutic effect is believed to be the antagonism of the calcium-sodium ion pump.^20,21
• Use of sodium thiosulfate may be considered as it has been shown to be effective in many cases of calciphylaxis. It would be considered off-label and experimental therapy.²²

Surgical Care

• Indications for surgical removal include pain, recurrent infection, ulceration, and functional impairment.
  • Because surgical trauma may stimulate calcification, initially treat a test site before pursuing a large excision.
  • Recurrence is common after excision.
• Electric shock wave lithotripsy is anecdotally successful in dermatomyositis-induced tissue calcification.²³
  • Although reduction in the size of the calcification was minimal, the patient's associated pain was completely relieved.
  • The physiology for this effect is unknown.

Consultations

• A nephrologist, a rheumatologist, and/or a hematologist should be consulted, as indicated by the underlying disease.

Diet

• Dietary alteration is of minor benefit in most cases.
• The following changes may be tried:
  • Restrict dietary phosphorous when hyperphosphatemia is present.
  • Restrict dietary calcium intake when hypercalcemia is present.
  • A ketogenic diet that stresses the consumption of free fatty acids may be helpful in some individuals. An accumulation of ketoacids, the metabolic product of fatty acids, may lower tissue pH and prevent crystallization.

Activity

• Activity is affected only if the calcified plaques and/or nodules are large enough to restrict joint mobility or cause ischemia and/or ulceration.

Medication

Medical therapy generally has limited benefit. The following medications may be tried.

Antacids

Inorganic salts can bind phosphate in the GI tract and prevent absorption.

Aluminum carbonate (Basaljel)

Increases gastric pH >4 and inhibits proteolytic activity of pepsin. Does not coat mucosal lining but may have local astringent effect. May increase tone of lower esophageal sphincter.

Dosing

Adult

400-1800 mg PO tid with meals

Pediatric

Not established

Interactions

Decreases effects of allopurinol, chloroquine, corticosteroids, diflunisal, digoxin, ethambutol, iron salts, H2-antagonists, isoniazid, penicillamine, phenothiazines, tetracyclines, thyroid hormones, and ticlopidine; increases effects of benzodiazepines and dicumarol

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Use in patients with renal insufficiency may result in aluminum toxicity; nausea and constipation are frequent adverse effects; aluminum ions inhibit smooth muscle contraction, inhibiting gastric emptying; caution in gastric outlet obstruction; may cause dose-related rebound hyperacidity by increasing gastric secretion or serum gastrin levels; prolonged use of aluminum-containing antacids in renal failure may result in or worsen dialysis osteomalacia; elevated tissue aluminum levels contribute to dialysis encephalopathy and osteomalacia syndromes

Aluminum hydroxide (ALternaGEL, Alu-Cap, Amphojel, Dialume)

Effective phosphate binder; not considered first-line therapy because of potential for toxicity.

Dosing

Adult

320-1800 mg PO tid with meals

Pediatric

50-150 mg/kg/d PO divided q4-6h; titrate to maintain normal serum phosphorus levels

Interactions

Tetracyclines, ranitidine, ketoconazole, benzodiazepines, penicillamine, phenothiazines, digoxin, indomethacin, isoniazids, and corticosteroids decrease effects of aluminum in hyperphosphatemia; absorption of dicumarol and benzodiazepines may increase if administered concurrently

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in patients with recent massive upper GI hemorrhage; renal failure may cause aluminum toxicity

Magnesium oxide (Maox, Mag-ox)

Treats magnesium deficiencies or magnesium depletion due to malnutrition, restricted diet, alcoholism, or magnesium-depleting drugs.

Dosing

Adult

140-420 mg PO tid with meals

Pediatric

Administer as in adults

Interactions

Decreases effects of benzodiazepines, chloroquine, corticosteroids, digoxin, H2-antagonists, hydantoins, nitrofurantoin, tetracyclines, iron salts, ticlopidine, phenothiazines, iron salts; increases the effects of dicoumarol, quinidine, and sulfonylureas

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Hypermagnesemia and toxicity may occur in renal impairment when magnesium >50 mEq is given qd because of decreased clearance of magnesium ion; approximately 5-20% of orally administered magnesium salts can be absorbed systemically

Diphosphonates

These agents are used to inhibit bone turnover to lower serum calcium and phosphate levels. These agents also can absorb hydroxyapatite crystal and inhibit growth.

Etidronate disodium (Didronel)

Reduces bone formation and does not alter renal tubular reabsorption of calcium. Does not affect hypercalcemia in patients with hyperparathyroidism.

Dosing

Adult

5 mg/kg/d PO for no longer than 6 mo

Pediatric

Not established

Interactions

Coadministration with calcium containing products and other multivalent cations decrease absorption

Contraindications

Documented hypersensitivity; hypocalcemia, renal impairment

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Adverse effects dose related and infrequent with 5 mg/kg/d PO; caution in renal insufficiency; maintain adequate intake of calcium and vitamin D during therapy; monitor hypercalcemia-related parameters (eg, serum calcium, phosphate, magnesium, potassium levels)

Calcium-channel blockers

Antagonism of calcium-sodium pump may diminish the intracellular calcium concentration, decreasing crystal formation.

Diltiazem hydrochloride (Cardizem)

For management of angina, supraventricular tachycardia, and hypertension. During depolarization, inhibits calcium ions from entering slow channels and voltage-sensitive areas of vascular smooth muscle and myocardium.

Dosing

Adult

240-480 mg/d PO

Pediatric

Not established

Interactions

May increase carbamazepine, digoxin, cyclosporine, theophylline levels; may cause bradycardia and decrease cardiac output when administered with amiodarone; may increase cardiac depression when administered with beta-blockers; cimetidine may increase levels

Contraindications

Documented hypersensitivity, severe CHF, sick sinus syndrome, second- or third-degree AV block, hypotension (<90 mm Hg systolic)

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Monitor blood pressure and heart rate during therapy; caution in renal or hepatic impairment; may increase LFT levels and hepatic injury may occur

Calcimimetics

Cinacalcet (Sensipar)

Directly lowers parathyroid hormone (PTH) levels by increasing sensitivity of calcium-sensing receptor on chief cell of parathyroid gland to extracellular calcium. Also results in concomitant serum calcium decrease.

Dosing

Adult

30 mg PO qd initially; titrate q2-4wk prn to normalize calcium levels by sequential doses of 30 mg bid, 60 mg bid, 90 mg bid, and 90 mg tid/qid; take with meals or immediately following; do not crush, chew, or cut tab

Pediatric

Not established

Interactions

Strong CYP450 2D6 inhibitor; may increase serum levels of CYP2D6 substrates (eg, flecainide, vinblastine, thioridazine, TCAs); coadministration with CYP450 3A4 inhibitors (eg, ketoconazole, erythromycin, itraconazole) may decrease clearance

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Serum calcium reduction may cause lowered seizure threshold, paresthesia, myalgia, cramping, and tetany; monitor calcium and phosphorus levels closely within 1 wk following initial dose or dose changes and then monthly (secondary hyperparathyroidism) and q2mo (parathyroid carcinoma); do not initiate treatment if serum calcium level <8.4 mg/dL; adynamic bone disease may occur if iPTH levels suppressed <100 pg/mL; caution with hepatic impairment; common adverse effects include nausea and vomiting

Follow-up

Deterrence/Prevention

• Prevention or treatment of the underlying disease process, as well as prevention of trauma and factors associated with iatrogenic calcinosis, is optimal.

Complications

• Complications of calcinosis cutis include pain, cosmetic disfigurement, ulceration, and mechanical compromise.
• The plaques or nodules may impinge on adjacent structures such as joints, resulting in restricted mobility, and nerves, resulting in pain or paresthesia.
• Destruction of synovial tissue also may result.
• Vascular occlusion may result in gangrene.
• Ulceration may be complicated by bacterial infection.

Prognosis

• The prognosis is determined by that of any underlying disease.
• Calcinosis cutis alone usually is benign.
• Severe complications are infrequent.

Patient Education

• Patients should be educated about the underlying disease processes and natural history of their specific disorder.

Multimedia

Media file 1: Calcinosis cutis appearing as an indurated and nodular subcutaneous plaque in a patient with systemic lupus erythematosus.

Media file 2: Ulceration of a lesion of calcinosis cutis in a patient with systemic lupus erythematosus.

References

1. Weinel S, Callen JP. Calcinosis cutis complicating adult-onset dermatomyositis. Arch Dermatol. Mar 2004;140(3):365-6. [Medline].

2. Yun SJ, Lee JB, Kim SJ, Lee SC, Won YH, Kang HC. Calcinosis cutis universalis with joint contractures complicating juvenile dermatomyositis. Dermatology. 2006;212(4):401-3. [Medline].

3. Marzano AV, Kolesnikova LV, Gasparini G, Alessi E. Dystrophic calcinosis cutis in subacute lupus. Dermatology. 1999;198(1):90-2. [Medline].

4. Miteva L, Pramatarov K, Vassileva S. Calcinosis cutis in childhood systemic lupus erythematosus. J Eur Acad Dermatol Venereol. Sep 2003;17(5):611-2. [Medline].

5. Rothe MJ, Grant-Kels JM, Rothfield NF. Extensive calcinosis cutis with systemic lupus erythematosus. Arch Dermatol. Aug 1990;126(8):1060-3. [Medline].

6. Tristano AG, Villarroel JL, Rodriguez MA, Millan A. Calcinosis cutis universalis in a patient with systemic lupus erythematosus. Clin Rheumatol. Feb 2006;25(1):70-4. [Medline].

7. Becuwe C, Roth B, Villedieu MH, Chouvet B, Kanitakis J, Claudy A. Milia-like idiopathic calcinosis cutis. Pediatr Dermatol. Jul-Aug 2004;21(4):483-5. [Medline].

8. Eckman JA, Mutasim DF. Bullous systemic lupus erythematosus with milia and calcinosis. Cutis. Jul 2002;70(1):31-4. [Medline].

9. Lee DW, Yoon DH, Lee YS, Shim SI, Cho BK. Solitary milialike idiopathic calcinosis cutis: a case unassociated with Down syndrome. J Dermatol. Jan 1996;23(1):53-5. [Medline].

10. Sais G, Jucglà A, Moreno A, Peyrí J. Milia-like idiopathic calcinosis cutis and multiple connective tissue nevi in a patient with Down syndrome. J Am Acad Dermatol. Jan 1995;32(1):129-30. [Medline].

11. Larralde M, Giachetti A, Kowalczuk A, D'Agostino D, Galimberti R. Calcinosis cutis following liver transplantation in a pediatric patient. Pediatr Dermatol. May-Jun 2003;20(3):225-8. [Medline].

12. Lateo S, Charlton F, Hudson M, Lawrence CM. Cutaneous calcification following liver transplantation. Clin Exp Dermatol. Sep 2005;30(5):484-6. [Medline].

13. Neau-Cransac M, Lepreux S, Labreze C, et al. Uncommon localization of calcinosis cutis after liver transplantation. Dermatology. 2005;211(4):379-81. [Medline].

14. Aksoy HM, Ozdemir R, Karaaslan O, Tiftikcioglu YO, Oruc M, Kocer U. Incidental idiopathic calcinosis cutis in a rhytidectomy patient. Dermatol Surg. Aug 2004;30(8):1145-7. [Medline].

15. Kannan S, Ravikumar L, Mahadevan S, et al. Tumoral calcinosis with vitamin D deficiency. Saudi J Kidney Dis Transpl. Nov 2008;19(6):960-3. [Medline].

16. Bhattacharya A, Prasad V, Thomas EJ, Singh B, Mittal BR. Tc-99m MDP scintigraphy in a case of idiopathic calcinosis cutis. Clin Nucl Med. Jun 2005;30(6):431-2. [Medline].

17. Larsen MJ, Adcock KA, Satterlee WG. Dermal uptake of technetium-99m MDP in calcinosis cutis. Clin Nucl Med. Nov 1985;10(11):780-2. [Medline].

18. Grases F, Perello J, Isern B, Prieto RM. Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis. Br J Dermatol. May 2005;152(5):1022-5. [Medline].

19. Grases F, Perello J, Isern B, Prieto RM. Study of the absorption of myo-inositol hexakisphosphate (InsP6) through the skin. Biol Pharm Bull. Apr 2005;28(4):764-7. [Medline].

20. Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol. Mar-Apr 2005;15(2):102-4. [Medline].

21. Palmieri GM, Sebes JI, Aelion JA, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum. Nov 1995;38(11):1646-54. [Medline].

22. Papadakis JT, Patrikarea A, Digenis GE, et al. Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism. Nephron. 1996;72(2):308-12. [Medline].

23. Chan AY, Li E. Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis-old method, new discovery. Clin Rheumatol. Apr 2005;24(2):172-3. [Medline].

24. Campanelli A, Kaya G, Masouye I, Borradori L. Calcifying panniculitis following subcutaneous injections of nadroparin-calcium in a patient with osteomalacia. Br J Dermatol. Sep 2005;153(3):657-60. [Medline].

25. De Beuckeleer LH, Vanhoenacker FM, Spinhoven M, Dieltjens A. Images in clinical radiology. Calcinosis cutis following calcium gluconate extravasation. JBR-BTR. Sep-Oct 2003;86(5):305. [Medline].

26. Eich D, Scharffetter-Kochanek K, Weihrauch J, Krieg T, Hunzelmann N. Calcinosis of the cutis and subcutis: an unusual nonimmunologic adverse reaction to subcutaneous injections of low-molecular-weight calcium-containing heparins. J Am Acad Dermatol. Feb 2004;50(2):210-4. [Medline].

27. Fitz-Henley M. Image and diagnosis. Cutaneous calcinosis (calcinosis cutis). West Indian Med J. Dec 2002;51(4):246, 272. [Medline].

28. Giorgini S, Martinelli C, Massi D, Lumini A, Mannucci M, Giglioli L. Iatrogenic calcinosis cutis following nadroparin injection. Int J Dermatol. Oct 2005;44(10):855-7. [Medline].

29. Ichikawa S, Imel EA, Sorenson AH, Severe R, Knudson P, Harris GJ, et al. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab. Nov 2006;91(11):4472-5. Epub 2006 Aug 29. [Medline].

30. Kacerovska D, Nemcova J, Pomahacova R, Michal M, Kazakov DV. Cutaneous and superficial soft tissue lesions associated with Albright hereditary osteodystrophy: clinicopathological and molecular genetic study of 4 cases, including a novel mutation of the GNAS gene. Am J Dermatopathol. Oct 2008;30(5):417-24. [Medline].

31. Lai CH, Farah R, Mallory SB. Congenital calcinosis cutis of the ear. J Am Acad Dermatol. Jul 2003;49(1):122-4. [Medline].

32. Mendoza LE, Lavery LA, Adam RC. Calcinosis cutis circumscripta. A literature review and case report. J Am Podiatr Med Assoc. Feb 1990;80(2):97-9. [Medline].

33. Morgan MB. Nanobacteria and calcinosis cutis. J Cutan Pathol. Mar 2002;29(3):173-5. [Medline].

34. Moss J, Syrengelas A, Antaya R, Lazova R. Calcinosis cutis: a complication of intravenous administration of calcium glucanate. J Cutan Pathol. Sep 2006;33 Suppl 2:60-2. [Medline].

35. Ogretmen Z, Akay A, Bicakci C, Bicakci HC. Calcinosis cutis universalis. J Eur Acad Dermatol Venereol. Nov 2002;16(6):621-4. [Medline].

36. Ozcelik B, Serin IS, Basbug M, Ozturk F. Idiopathic calcinosis cutis of the vulva in an elderly woman. A case report. J Reprod Med. Jul 2002;47(7):597-9. [Medline].

37. Palamaras I, Kyriakis K. Calcium antagonists in dermatology: a review of the evidence and research-based studies. Dermatol Online J. 2005;11(2):8. [Medline].

38. Plott T, Wiss K, Raimer SS, Solomon AR. Recurrent subepidermal calcified nodule of the nose. Pediatr Dermatol. May 1988;5(2):107-11. [Medline].

39. Puvabanditsin S, Garrow E, Titapiwatanakun R, Getachew R, Patel JB. Severe calcinosis cutis in an infant. Pediatr Radiol. May 2005;35(5):539-42. [Medline].

40. Rodriguez-Cano L, Garcia-Patos V, Creus M, Bastida P, Ortega JJ, Castells A. Childhood calcinosis cutis. Pediatr Dermatol. Mar-Apr 1996;13(2):114-7. [Medline].

41. Sanchez-Merino JM, Bouso-Montero M, Fernandez-Flores A, Garcia-Alonso J. Idiopathic calcinosis cutis of the penis. J Am Acad Dermatol. Aug 2004;51(2 Suppl):S118-9. [Medline].

42. Satter EK, Maari CH, Morel KD, et al. Disseminated linear calcinosis cutis associated with the Koebner phenomenon in an infant with congenital acute monocytic leukaemia. Br J Dermatol. Apr 2004;150(4):753-6. [Medline].

43. Smack D, Norton SA, Fitzpatrick JE. Proposal for a pathogenesis-based classification of tumoral calcinosis. Int J Dermatol. Apr 1996;35(4):265-71. [Medline].

44. Takahama H, Noto S, Ito M, Nishimoto H, Tadokoro M. A case of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber's disease) with dystrophic calcinosis cutis and retinal lesions. J Dermatol. Aug 2002;29(8):512-5. [Medline].

45. Tomizawa K, Tanaka S, Saito B, Ota K. A peculiar type of dystrophic calcinosis cutis affecting the surface of damaged genital skin and mucosa in an elderly woman with a vesicovaginal fistula. Br J Dermatol. Jan 2004;150(1):169-71. [Medline].

46. Touart DM, Sau P. Cutaneous deposition diseases. Part II. J Am Acad Dermatol. Oct 1998;39(4 Pt 1):527-44; quiz 545-6. [Medline].

47. Valdatta L, Buoro M, Thione A, et al. Idiopathic circumscripta calcinosis cutis of the knee. Dermatol Surg. Dec 2003;29(12):1222-4. [Medline].

48. Viegas SF, Evans EB, Calhoun J, Goodwiller SE. Tumoral calcinosis: a case report and review of the literature. J Hand Surg [Am]. Sep 1985;10(5):744-8. [Medline].

49. Walsh JS, Fairley JA. Calcifying disorders of the skin. J Am Acad Dermatol. Nov 1995;33(5 Pt 1):693-706; quiz 707-10. [Medline].

50. Wozniak F, Maslankiewicz B. Idiopathic calcinosis cutis of the scrotum and penis. Ann Univ Mariae Curie Sklodowska [Med]. 1990;45:107-9. [Medline].

Keywords

cutaneous calcinosis, cutaneous calculi

Contributor Information and Disclosures

Author

Julia R Nunley, MD, Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center
Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, and Women's Dermatologic Society
Disclosure: Johnson and Johnson stock holder dividends; Amgen stock holder dividends; Forest Lab, Inc stock holder dividends; Galaxo Smith Klein stock holder dividends; Covidien stock holder dividends; Novartis Grant/research funds Consulting; Biolex  sub-investigator

Coauthor(s)

Lydia M E Jones, MD, Staff Physician, Department of Dermatology, Virginia Commonwealth University
Disclosure: Nothing to disclose.

Medical Editor

James W Patterson, MD, Director of Dermatopathology, Professor of Pathology and Dermatology, Departments of Pathology and Dermatology, University of Virginia Medical Center
James W Patterson, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Medical Association, American Society of Dermatopathology, Medical Society of Virginia, Royal Society of Medicine, Society for Investigative Dermatology, and United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.

Pharmacy Editor

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA
Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Rosalie Elenitsas, MD, Herman Beerman Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System
Rosalie Elenitsas, MD is a member of the following medical societies: American Academy of Dermatology and American Society of Dermatopathology
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System
William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology
Disclosure: elsevier Royalty Other; american college of physicians Honoraria Other

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)